Abbott Q4 2021 Earnings Report
Key Takeaways
Abbott announced strong fourth-quarter and full-year 2021 financial results. The company's worldwide sales increased 7.2 percent on a reported basis and 7.7 percent on an organic basis. Abbott projects full-year 2022 diluted earnings per share from continuing operations under GAAP of at least $3.43.
Worldwide sales increased 7.2 percent on a reported basis and 7.7 percent on an organic basis.
Global COVID-19 testing-related sales were $2.3 billion.
FreeStyle Libre® sales were $1.0 billion, representing sales growth of 35.4 percent on a reported basis.
Abbott projects full-year 2022 diluted earnings per share from continuing operations under GAAP of at least $3.43.
Abbott
Abbott
Forward Guidance
Abbott projects full-year 2022 diluted earnings per share from continuing operations under GAAP of at least $3.43. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be at least $4.70 for the full-year 2022. Abbott projects first-quarter 2022 diluted earnings per share from continuing operations under GAAP of at least $1.20. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be at least $1.50 for the first quarter.